U.S. market Closed. Opens in 13 hours 15 minutes

CATX | Perspective Therapeutics, Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 13.28 - 13.93
52 Week Range 2.2000 - 19.10
Beta 1.70
Implied Volatility 315.16%
IV Rank 47.45%
Day's Volume 657,687
Average Volume 912,706
Shares Outstanding 67,427,700
Market Cap 900,159,795
Sector Healthcare
Industry Medical - Devices
IPO Date 2005-11-10
Valuation
Profitability
Growth
Health
P/E Ratio -9.08
Forward P/E Ratio N/A
EPS -1.47
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 116
Country USA
Website CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX's peers: KIDS, OFIX, SGHT, NPCE, CVRX, PAVM, OSA, HYPR, ELMD, SRDX, FNA, LIVN, LUNG, SIBN
*Chart delayed
Analyzing fundamentals for CATX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong. For more detailed analysis please see CATX Fundamentals page.

Watching at CATX technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on CATX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙